Butterfly Network, Inc.
$5.40-$0.45 (-7.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.4B
- Revenue
- $97.6M
- Net margin
- -78.9%
- ROCE
- -38.5%
Price chart
Technical chartScreen technicals →+132.8% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -26.1%
- 3M
- -41.1%
- 6M
- +23.0%
- 1Y
- +132.8%
- 5Y
- -32.5%
52-week range
Day change -$0.45 (-7.7%) from $5.85 to $5.40 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in BFLY, bought on each weekday since 2021.
News & filings
What Butterfly Network filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 77.1 million US dollars in fiscal 2025.
Strengths (1)
- Revenue grew 19.0% in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally.
Read moreShow less
Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 253.8M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.4B
- P/B
- 6.9x
- EV / Sales
- 12.6x
- P/S
- 13.9x
- 52-week high
- $9.93
- 52-week low
- $2.32
Profitability
- Operating margin
- -88.5%
- Net margin
- -78.9%
- EBITDA margin
- -69.0%
- ROE
- -39.3%
- ROCE
- -38.5%
- ROIC
- -90.5%
- ROA
- -26.0%
- Asset turnover
- 0.33
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $97.6M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 19.0%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 10.0%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 6.3%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$16.0M
Solvency
- Current ratio
- 3.83
- Debt / Equity
- 0.10
- Debt / Assets
- 0.07
- CFO / Net profit
- 0.16
- Cash / Market cap
- 11.1%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $97.6M |
| Cost of revenue | $51.9M |
| Gross profit | $45.7M |
| Operating expenses | $132.2M |
| Research and development | $36.3M |
| Selling, general and administrative | $95.9M |
| Operating income | -$86.4M |
| Interest and other | $9.5M |
| Pretax income | -$77.0M |
| Tax and other | $110.0k |
| Net income | -$77.1M |
Revenue and net profit
Revenue grew 19.0% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $73.4M | -$168.7M |
| FY2023 | $65.9M | -$133.7M |
| FY2024 | $82.1M | -$72.5M |
| FY2025 | $97.6M | -$77.1M |
Cash flows
FY2025: -$12.7M from operations, -$16.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$169.1M | -$187.4M |
| FY2023 | -$98.8M | -$104.6M |
| FY2024 | -$41.7M | -$44.4M |
| FY2025 | -$12.7M | -$16.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $97.6M+19.0%1Y
- EBITDA
- -$67.4M
- Net profit
- -$77.1M
- Cash from operations
- -$12.7M
- Free cash flow
- -$16.0M
- Revenue CAGR, 3Y
- 10.0%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $97.6M | -$67.4M | -$77.1M | -$16.0M | -39.3% | +19.0% | +6.3% |
Monthly returns
Month-by-month returns of BFLY across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $296.5M |
| Current assets | $249.1M |
| Non-current assets | $47.4M |
| Liabilities | $100.5M |
| Current liabilities | $65.1M |
| Non-current liabilities | $35.4M |
| Equity | $196.0M |
| Paid-in capital | $1.1B |
| Retained earnings | -$879.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; BFLY highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): MapLight Therapeutics, Inc., Bicara Therapeutics Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Butterfly Network, Inc.BFLYthis company | $1.4B | — | 6.9x | -39.3% | — |
| AtriCure, Inc.ATRC | $1.4B | -120.6x | 2.8x | -2.3% | 79.2x |
| Precigen, Inc.PGEN | $1.4B | -5.5x | 65.8x | -1198.6% | -5.9x |
| Integra LifeSciences Holdings CorporationIART | $1.4B | -2.6x | 1.3x | -49.5% | -9.7x |
| MapLight Therapeutics, Inc.MPLT | $1.4B | — | 3.0x | -35.2% | — |
| UroGen Pharma Ltd.URGN | $1.3B | -8.8x | -12.7x | 145.5% | -10.0x |
| Bicara Therapeutics Inc.BCAX | $1.3B | -9.7x | 3.3x | -34.4% | -8.0x |
| Inhibrx Biosciences, Inc.INBX | $1.3B | -9.6x | 167.5x | -1752.2% | -10.5x |
| Ardelyx, Inc.ARDX | $1.3B | -21.7x | 8.0x | -36.9% | -50.5x |
| Peer median | — | -9.6x | 3.2x | -36.0% | -9.7x |
Year-to-date ROI
BFLY since 1 January, against earlier years.
Historical volatility
BFLY's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -263.0% |
| FY2023 | -221.0% |
| FY2024 | -90.7% |
| FY2025 | -88.5% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $97.6M |
| Cost of revenueCost Of Revenue | $51.9M |
| Gross profitGross Profit | $45.7M |
| Operating expensesOperating Expense | $132.2M |
| Research and developmentResearch And Development | $36.3M |
| Selling, general and administrativeSelling General And Administration | $95.9M |
| Other operating expensesOther Operating Expenses | — |
| Total expensesTotal Expenses | $184.0M |
| Operating incomeOperating Income | -$86.4M |
| Interest and other | |
| Pretax incomePretax Income | -$77.0M |
| TaxTax Provision | $110.0k |
| Net incomeNet Income | -$77.1M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $296.5M |
| Current assetsCurrent Assets | $249.1M |
| Non-current assetsTotal Non Current Assets | $47.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $100.5M |
| Current liabilitiesCurrent Liabilities | $65.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $35.4M |
| EquityTotal Equity Gross Minority Interest | $196.0M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$12.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$12.7M |
| Net income, continuing operationsNet Income From Continuing Operations | -$77.1M |
| Depreciation and amortisationDepreciation And Amortization | $8.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $8.1M |
| Depreciation | $8.1M |
| Stock-based compensationStock Based Compensation | $23.4M |
| Operating gains and lossesOperating Gains Losses | -$2.3M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$2.3M |
| Asset impairmentAsset Impairment Charge | $17.6M |
| Change in working capitalChange In Working Capital | $15.2M |
| Other non-cash itemsOther Non Cash Items | $2.3M |
| Investing cash flowInvesting Cash Flow | -$3.4M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$3.4M |
| Capital expenditureCapital Expenditure | -$3.4M |
| Purchase of PP&EPurchase Of PPE | -$3.4M |
| Sale of PP&ESale Of PPE | $0.00 |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$3.4M |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Financing cash flowFinancing Cash Flow | $77.8M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $77.8M |
| Debt issuedIssuance Of Debt | — |
| Debt repaidRepayment Of Debt | — |
| Net debt issuedNet Issuance Payments Of Debt | — |
| Long-term debt issuedLong Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | — |
| Net long-term debt issuedNet Long Term Debt Issuance | — |
| Shares issuedIssuance Of Capital Stock | $81.0M |
| Common stock issuedCommon Stock Issuance | $81.0M |
| Net common stock issuedNet Common Stock Issuance | $81.0M |
| Stock options exercisedProceeds From Stock Option Exercised | $2.2M |
| Other financing chargesNet Other Financing Charges | -$5.5M |
| Change in cashChanges In Cash | $61.7M |
| Cash at the start of the yearBeginning Cash Position | $92.8M |
| Cash at the end of the yearEnd Cash Position | $154.5M |
| Free cash flowFree Cash Flow | -$16.1M |
| Supplemental |
Learn while you research
Academy chapters picked for Butterfly Network, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read